Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial

Study limitation reported by the research below: “Participants at high risk of hospitalisation or death were excluded, limiting generalisability to higher-risk populations where nirmatrelvir-ritonavir is most commonly indicated.”